Company: ENTXW
Filing Date: 2025-07-18
Form Type: 8-K
Source: 0001178913-25-002406
Chunk: 0

Company: Entera Bio Ltd.
Filing Date: 2025-07-18
Form: 8-K
Item: Item 5.07
Chunk 0
---
Item 5.07 Submission of Matters to a Vote of Security Holders.

Entera Bio Ltd., a company organized under the laws of the State of Israel (the “ Company”), held its 2025 Annual Meeting of Shareholders on July 16, 2025 (the “ Annual Meeting”). The final voting
results for the proposals submitted to a vote of the Company’s shareholders at the Annual Meeting are as follows:

Proposal 1: Election of Haya Taitel to the Board of Directors of the Company for a three-year term to hold office until the Company’s
2028 Annual Meeting of Shareholders or until her successor is elected:

  Votes           Votes                           Broker     
  For             Against        Abstentions      Non-Votes  
 ─────────────────────────────────────────────────────────────
  17,288,920      3,069,140      137,907          6,197,026  

Proposal 2: Ratification and approval of revised compensation terms and a one-time grant of compensation, as described in the
Company’s Definitive Proxy Statement on Schedule 14A (the “ Proxy Statement”) filed with the Securities and Exchange Commission on June 5, 2025, in connection
with the Annual Meeting, relating to Ms. Miranda Toledano, the Company’s Chief Executive Officer and a Director:

  Votes           Votes                         Broker     
  For             Against      Abstentions      Non-Votes  
 ───────────────────────────────────────────────────────────
  19,524,783      428,993      542,191          6,197,026  

Proposal 3: Ratification and approval of revised compensation terms and a one-time grant of compensation, as described in the Proxy
Statement, relating to Dr. Gregory Burshtein, the Company’s Chief of Research & Development:

  Votes           Votes                           Broker     
  For             Against        Abstentions      Non-Votes  
 ─────────────────────────────────────────────────────────────
  16,518,134      3,435,638      542,195          6,197,026  

Proposal 4: Ratification and approval of revised compensation terms and a one-time grant of compensation, as described in the Proxy
Statement, relating to Ms. Dana Yaacov-Garbeli, the Company’s Chief Financial Officer:

  Votes           Votes                         Broker     
  For             Against      Abstentions      Non-Votes  
 ─────────────────────────────────────────